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Pathogenic Mitochondrial DNA Mutations
Are Common in the General Population
Hannah R. Elliott,1 David C. Samuels,2 James A. Eden,3 Caroline L. Relton,3 and Patrick F. Chinnery1,3,*
Mitochondrial DNA (mtDNA) mutations are a major cause of genetic disease, but their prevalence in the general population is not
known. We determined the frequency of ten mitochondrial point mutations in 3168 neonatal-cord-blood samples from sequential
live births, analyzing matched maternal-blood samples to estimate the de novo mutation rate. mtDNA mutations were detected in
15 offspring (0.54%, 95% CI ¼ 0.30–0.89%). Of these live births, 0.00107% (95% CI ¼ 0.00087–0.0127) harbored a mutation not de-
tected in the mother’s blood, providing an estimate of the de novo mutation rate. The most common mutation was m.3243A/
G. m.14484T/C was only found on sub-branches of mtDNA haplogroup J. In conclusion, at least one in 200 healthy humans harbors
a pathogenic mtDNA mutation that potentially causes disease in the offspring of female carriers. The exclusive detection of
m.14484T/C on haplogroup J implicates the background mtDNA haplotype in mutagenesis. These ﬁndings emphasize the importance
of developing new approaches to prevent transmission.
Introduction
Disease-based epidemiological studies provide estimates of
the minimum population prevalence of mtDNA disease as
~1 in 5000,
1–6 but the incidence of new mutations and the
frequency of asymptomatic carriers have not been fully es-
tablished. Fundamental differences between mtDNA in-
heritance and the Mendelian system mean that de novo
mutation rates and carrier frequencies cannot be deduced
with a standard Mendelian population-genetic approach.
Strict maternal inheritance results in negligible intermo-
lecular recombination apparent at the population level,
and the presence of thousands of copies of mtDNA within
each diploid mammalian cell adds a further complexity.
7
Most pathogenic mtDNA mutations are heteroplasmic,
with varying amounts of mutated mtDNA present within
each cell.
8 Phenotypic expression is ultimately dependent
upon the proportion of mutated mtDNA or the amount of
wild-type mtDNA within vulnerable tissues. This only
leads to a biochemical defect of the respiratory chain
when a critical threshold level is exceeded, with the precise
amount varying from mutation to mutation.
8 In keeping
with this, a family with mitochondrial disease usually pres-
ents clinically for the ﬁrst time when an individual inherits
a high proportion of mutated mtDNA from a mother who
harbors a low levelof mutated mtDNAand remainsasymp-
tomatic. Such dramatic changes in heteroplasmy can occur
in a single generation because of a restriction in the intra-
cellular mtDNA content during embryonic development
that is responsible for the mtDNA genetic bottleneck.
9
Previous estimates of the carrier frequency of mtDNA
mutations were largely based on the ascertainment of ped-
igrees through one or more clinically affected individuals,
followed by careful family tracing of the maternal line-
age.
1–6 This raises the possibility that de novo mtDNA mu-
tations remain undetected in the population because they
are well below the threshold required for phenotypic ex-
pression or because they lie below the detection threshold
of conventional sequencing. Many of these mutations
would be lost through random genetic drift, causing dis-
ease only when the percentage level of mutation drifts up-
wards in one or more family members and exceeds the
threshold required for clinical presentation.
A further complication is the strong association between
speciﬁc pathogenic mtDNA mutations and closely related
mtDNA polymorphisms (haplogroups), which is not
thought to be due to a founder effect.
10,11 However, it is
not known whether the polymorphisms that deﬁne the
haplogroup predispose it to de novo mutation events,
whether they cause the preferential segregation of patho-
genic mutations, or whether they affect clinical expression
oftheassociated disorder.The only wayofaddressing these
issues is by screening a large random sample of the popula-
tion, with matched maternal samples, to determine
whether the detected mutations are de novo or inherited.
Material and Methods
We measured the frequency of the ten pathogenic mtDNA muta-
tions often found in patients with mitochondrial disease
(m.1555A/G, m.3243A/G, m.3460G/A, m.7445A/G,
m.8344A/G, m.8993T/G, m.11778G/A, m.13513G/A,
m.14459G/A, m.14484T/C) in ~3000 sequential umbilical-
cord-blood samples from north Cumbria in England.
12 Consent
for inclusion into the study exceeded 80%. Ethical approval to in-
vestigate mtDNA mutations within this cohort was granted by
the West Cumbria Local Research Ethics Committee (Project
381). Previous epidemiological and nuclear genetic studies estab-
lished that this cohort is a random sample of the population with
numerous nuclear alleles in Hardy-Weinberg equilibrium.
13
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The ten major European mtDNA haplogroups were determined in
344 random samples from the cohort as described in the litera-
ture,
14 with the use of modiﬁed primer sequences. This conﬁrmed
that the study group was representative of the UK population
(Table 1). Mitochondrial haplogroups were also determined in
samples that harbored mtDNA point mutations and in their
mothers, with the same approach used.
High-Throughput Genotyping
The population was genotyped by primer extension of multiplex
PCR products with the detection of the allele-speciﬁc extension
products by matrix-associated laser desorption/ionization time
of ﬂight (MALDI-TOF; Sequenom MassARRAY, San Diego, CA).
Assays were designed with Sequenom Assay Design software
v2.0.7.0, resulting in ﬁve multiplex assays. The allelotyping assay
was followed according to manufacturer’s instructions, with mod-
iﬁcations. At the primary PCR step, DNA was ampliﬁed under the
following conditions: initial denaturation of 95 C for 15 minutes,
then 30 cycles of denaturation at 95 C for 20 seconds, annealing
at 60 C for 30 seconds, and extension at 72 C for 1 minute. Fi-
nally, there was a further extension at 72 C for 3 minutes before
the samples were cooled and stored at 4 C. A homogeneous Mas-
sEXTEND (hME) reaction mix containing appropriate hME
EXTEND mix (13 buffer with 0.225 mM d/ddNTPs), 2.7 mM
MassEXTEND primer, and 0.576 U ThermoSequenase (GE Health-
care), made up to a ﬁnal volume of 2 mL with anH2O, was added to
each SAP-cleaned PCR product. The microplate was then thermo-
cycled as follows: initial denaturation of 94 C for 2 minutes, then
55 cycles of denaturation at 94 C for 5 seconds, annealing at 52 C
for 5 seconds, and extension at 72 C for 5 seconds before cooling
to 4 C. The sample microplate and a 384 SpectroCHIP were loaded
onto the deck of the Samsung Nanodispenser. 15 nL of solution
from the sample microplate was transferred onto the chip, which
was read by a Bruker Autoﬂex Mass Spectrometer system. Data was
collected with the use of SpectroACQUIRE v3.3.1.3 software and
visualised with the use of MassARRAY Typer v3.4 TyperAnalyzer
software. The sensitivity of the MALDI-TOF MS assay for each mu-
tation was assessed with mixed cloned mtDNA fragments in dupli-
cate for both uniplex and multiplex reactions (Table S1, available
online).
The assay detected R 10% mutated mtDNA in each case, and for
some mutations, the detection threshold was considerably lower
(Table S1). For nine mutations, positive calls were conﬁrmed by
direct sequencing and last-cycle ﬂuorescent PCR-RFLP from an
independent aliquot of DNA, which established the percentage
mutated mtDNA (see below). The m.1555A/G mutation was
conﬁrmed by cloning and sequencing from a separate aliquot of
DNA from the same subject.
Measurement of mtDNA Heteroplasmy
Positive calls were conﬁrmed in an independent aliquot from the
original DNA sample with the use of last-cycle ﬂuorescent PCR-
RFLP as described previously.
15 This also established the percent-
age mutated mtDNA. For the m.1555A/G mutation, hetero-
plasmy was quantiﬁed by cloning and sequencing of 23 indepen-
dent mtDNA fragments from an independent aliquot from the
original DNA sample. Primers and restriction enzymes and digests
are shown in Table S2.
MtDNA Sequencing
The mitochondrial noncoding control region (D-loop) was se-
quenced by PCR of four overlapping segments, with the use of for-
ward and reverse M13-tagged primer pairs. Primer sequences are
shown in Table S3. PCR products were treated with ExoSAP (Exo-
SAP-IT, GE Healthcare, USA) and sequenced on a ﬂuorescent ge-
netic analyzer (Beckman-Coulter CEQ 8000) with the standard di-
deoxy chain-termination method (Beckman-Coulter Quickstart).
The sequence data were compared to the revised Cambridge refer-
ence sequence (rCRS)
16 with the use of CEQ Sequence Analysis
v2.3.13 analysis software (Beckman-Coulter). This allowed identi-
ﬁcation of D-loop changes and comparison of positive samples.
Statistical Analysis
Frequencies were compared by calculation of empirical P-values
with a Monte Carlo-based simulation approach based on the
method of Roff and Bentzen.
17 Exact 95% conﬁdence intervals
were calculated by the Clopper-Pearson method.
18
Results
Population Prevalence
Known duplicate samples from the same individual were
100% concordant. mtDNA mutations were detected in 15
different subjects (Table 2), giving a total mean frequency
of 0.54% for the ten mutations (95% CI ¼ 0.30–0.89%) in
neonatal-cord-blood samples. The m.3243A/G mutation
was the most common. No positive calls were seen for ﬁve
mutations: m.7445A/G, m.8344A/G, m.8993T/G,
m.13513G/A,andm.14459G/A.Ineachcase,themuta-
tion was conﬁrmed by an independent technique from
afreshaliquotofthesourceDNA,whichwaskeptinadiffer-
ent laboratory. For the majority of mutations, this was per-
formed with last-cycle ﬂuorescent PCR/RFLP, as described
in the Material and Methods section. For m.1555A/G,
the presence of the mutation was conﬁrmed in each case
by cloning and sequencing 23 independent clones.
Table 1. mtDNA Haplogroup Distribution in 344 Random Umbilical-Cord-Blood Samples from North Cumbria, England
mtDNA Haplogroup
H U T J W V I X M Other Total
n 137 79 45 34 14 12 7 7 1 8 344
% 39.83 22.97 13.08 9.88 4.07 3.49 2.03 2.03 0.29 2.33 100
95% CI 34.61–45.21 18.62–27.78 9.70–17.11 6.90–13.54 2.24–6.73 1.82–6.01 0.82–4.15 0.82–4.15 < 0.01–1.61 1.01–4.53
95% CI ¼ Exact 95% conﬁdence interval. The haplogroup U data includes the K subgroup. There were 27 subjects who belonged to the K subgroup of
haplogroup U (K ¼ 7.85% of the entire control cohort, 95% CI ¼ 5.24–11.21).
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tion. The mean heteroplasmy level for the 15 positive cases
was43% when homoplasmic mutations were includedand
29% when homoplasmic mutations were excluded. The
percentage level of mutant mtDNA was evenly distributed
above and below the mean (Figure 1). The three homoplas-
mic subjects, including two known siblings, harbored an
LHON mutation. D-loop sequencing and mtDNA hap-
logroup analysis conﬁrmed that other mutation-positive
caseswerenotmaternallyrelatedtoeachotherortoknown
pedigreesfromthesamegeographicregion,whichhadadif-
ferent mtDNA sequence at two or more sites
19 (Table 3).
Mutations Not Present in Maternal Samples
No matched maternal sample was available for seven of the
positive cases, but in eight cases it was possible to study
a maternal blood sample taken at the time of delivery of
the offspring. mtDNA mutations were not detectable in
the blood of three mothers, with one harboring
m.11778G/A, and two harboring m.3243A/G. This
provides an approximation of the de novo mutation
for mtDNA defects at 107/100,000 live births (95% CI ¼
87–127). Two of the mothers, accounting for the three
homoplasmic offspring with LHON mutations, were also
homoplasmic for the mtDNA mutation.
MtDNA Haplogroup Association
When the carriers of mtDNA mutations were studied to-
gether, the frequency of the major European haplogroups
was no different from the background population (Hap-
logroup H, p ¼ 1.0; J, p ¼ 0.1; U including subgroup K,
p ¼ 0.1; T, p¼ 1). However, all ofthe m.14484T/C carriers
belonged to haplogroup J (p ¼ 0.011, based on a compari-
son of the two index cases to the background-population
data in Table 1). This was not the case for the other two
LHON mutations, m.3460G/A and m.11778A/G. Sub-
haplogroup analysis of the two m.14484T/C pedigrees
on the basis of mtDNA D-loop sequencing (Table 3)
showed that one family belonged to J2a (siblings 4607-1
and 0493-1 harbored m.16069T, m.16126C, m.150T,
m.152C, m. 195C, m.16145A, and m.16231C) and the
other to J1c (02966 harbored m.16069T, m.16126C,
m.462T, and m.228A but is wild-type at m.152, m16145,
m.16222, and m.16261).
11
Discussion
Previous studies were based on ascertainment through
clinically affected subjects,
1–6 were focused on one speciﬁc
Table 2. The Frequency of Ten Pathogenic mtDNA Mutations in North Cumbria, England
mtDNA Mutation 1555A/G 3243A/G 3460G/A 7445A/G 8344A/G 8993T/G 11778G/A 13513G/A 14459G/A 14484T/C
Positive Calls 2 4 3 0 0 0 3 0 0 3
a
4755-1 T
(4.4%),
4394-1 H
(32.7%),
2728-1 T
(18.4%),
3530-1 K
(100.0%),
a4607-1 J
(100.0%),
MtDNA
Haplogroup
b
5798-1 J
(4.4%)
5218-1 H
(10.2%),
2916-1 H
(42.5%),
5841-1 H
(74.8%),
a0493-1 J
(100.0%),
(Percentage of
Mutated mtDNA)
5130-1 U
(1.7%),
0060-1 H
(12.9%)
0282-1 K
(56.5%)
2966-1 J
(89.1%)
5025-1 H
(0.5%)
No. of Successful
Genotypes
2751 2810 2807 2907 2770 2835 2770 2717 2676 2855
Frequency % 0.07 0.14 0.11 0 0 0 0.11 0 0 0.11
(95% CI) (0.01–0.26) (0.04–0.36) (0.02–0.31) (0–0.13) (0–0.13) (0–0.13) (0.02–0.32) (0–0.14) (0–0.14) (0.02–0.31)
For nine mutations, the percentage of mutated mtDNA was determined by last-cycle ﬂuorescent PCR. For m.1555A/G, heteroplasmy was quantiﬁed by
cloning and sequencing of independent mtDNA fragments. The detection threshold for the m.1555A/G mutation could not be quantiﬁed because of
a lack of an efﬁcient ﬂuorescent RFLP assay. However, dilution curves similar to those demonstrated estimated the assay to be efﬁcient in detecting
low levels of heteroplasmy. Quantiﬁcation by cloning and sequencing of mtDNA fragments of the lowest dilution positively identiﬁed by MALDI-TOF MS
indicated that the threshold of detection for m.1555A/G was 1.4% (1 of 70 independent clones).
a Two of these three subjects were known to be siblings. CI denotes conﬁdence interval.
b MtDNA haplogroup refers to the individual positive cases and their associated mtDNA haplogroup. The number is the case identiﬁer; the letter refers to
the European mtDNA haplogroup. K indicates the K subgroup of haplogroup U.
Figure 1. Percentage of Mutated mtDNA in the 15 Mutation-
Positive Cases
Red: m.14484T/C; blue: m.11778G/A; green: m.3460G/A;
black: m.3243A/G; orange: m.1555A/G.
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Subject ID rCRS
1555A/G 3243A/G 14484T/C 3460G/A 11778G/A
4755-1 5798-1 4394-1 4394-0
a 5218-1 5218-0
a 5130-1 5130-0
a 5025-1 5025-0
a 4607-1 4607-0
a 0493-1 02966 02728 02916 00060 3530-1 3530-0
a 5841-1 5841-0
a 00282
Haplogroup H T J H HH HU UH HJ JJ J T H H K KH HK
mtDNA np
22 T - - - - C C
a -- -- -- -- - - - -- -- -
7 3 A G G - -- -G G
a -- GG
a GG G --GG
a -- G
1 5 0 C - - - -- -T T
a -- TT
a T ----- - - - -
1 5 2 T C - - -- -- -- -C C
a C- C - - CC
a -- -
1 9 5 T C - - -- -- -- -C C
a C ----- - - - -
200 A - - G G
a -- -- -- -- -- - - - -- -- -
2 2 8 G - - - -- -- -- -- -- A - - - - -- --
2 4 2 C - T - -- -- -- -- -- - - - - - -- --
263 A G G G G
a G G
a G G
a G G
a G G
a G GGGGG G
a G G
a G
2 9 5 C - T - -- -- -- -T T
a T T---- - - - -
3 0 9 C - - - -- -- -- -- -- - - - - - -- --
309 Insþ1- C - C C
a C C
a -- -- TT
a T- - - C -- CC
a -
309 Insþ2 - --C- -- -- -- -- -- - - - -- CC
a -
3 1 5 C - - - -- -- -- -- -- - - - - - -- --
315 Insþ1- C C C C
a C C
a C C
a C C
a C C
a C CCCCC C
a C C
a C
3 1 9 T - - - -- -- -- -C C
a C ----- - - - -
4 6 2 C - T - -- -- -- -- -- T - - - - -- --
4 8 2 C - - - -- -- -- -- -- T - - - - -- --
4 8 9 T - C - -- -- -- -C C
a C C---- - - - -
4 9 7 C - - - -- -- -- -- -- - - - - T T
a -- T
5 1 3 G - - - -- -- -- -A A
a A----- - - - -
5 2 5 C - - - -- -- -- -- -- - - - - - -- --
525 Insþ1 - ---- -- -- -- -- -- - - - CC
a -- -
525 Insþ2 - ---- -- -- -- -- -- - - - AA
a -- -
525 Insþ3 - ---- -- -- -- -- -- - - - CC
a -- -
525 Insþ4 - ---- -- -- -- -- -- - - - AA
a -- -
15833 C - - - - - - - - - - - - - - - - T - - - - -
15928 G A - - - - - - - - - - - - - A - - - - - - -
16069 C - T - - - - - - - - T T
a T T---- - - - -
16093 T - - - - C C
a -- CC
a -- -- - - - -- CC
a -
16126 T C C - - - - - - - - C C
a C C C - - - -- --
16129 G - - - - - - - - - - - - - - - - - - - A A
a -
16145 G - A - - - - - - - - A A
a A----- - - - -
16163 A G - - - - - - - - - - - - - - - - - - - - -
16172 T - C - - - - - - - - - - - - - - C - - - - -
16186 C T - - - - - - - - - - - - - - - - - - - - -
16189 T C - - - - - - - - - - - - - - - - - - - - -
16192 C - T - - - - - - - - - - - - - - - - - - - -
16222 C - T - - - - - - - - - - - - - - - - - - - -
16224 T - - - - - - - - - - - - - - - - - C C
a -- C
16231 T - - - - - - - - - - C C
a C ----- - - - -
(continued on next page)
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7mutation,
20 and studied unrelated older subjects
20 in
whom somatic mutation or mutation loss through segrega-
tion are potential confounding factors. We studied ran-
domly ascertained neonatal-cord-blood samples in which
the percentage level of mutation is likely to be at its highest
level.
15,21,22 By studying ten-point mutations in ~3000
subjects, we detected a pathogenic mtDNA mutation in
> 1/200 live births. It is unlikely that the high frequency
of mtDNA mutations detected in the general population
in this study was due solely to the use of a sensitive tech-
nique, because other mutation-speciﬁc studies reported
a similar level of sensitivity (~2–3% for m.3243A/
G
2,5,23). It is also unlikely that our positive results were
due to crosscontamination, because we conﬁrmed each re-
sult using a different method on an independent aliquot of
the source DNA, which was kept in another laboratory; we
saw no evidence of heteroplasmy on the haplogroup RFLP
assays; and, ﬁnally, we saw no heteroplasmic nucleotides
on the D-loop sequence trace for each positive case. It is
conceivable that, in some subjects, we did not detect an
mtDNA mutation because the level of heteroplasmy either
fell below the sensitivity of our high-throughput screening
assay or was at higher percentage levels in other tissues.
Our observations, therefore, provide a minimum ﬁgure
for the prevalence of ten pathogenic mutations and indi-
cate that mtDNA mutations are amongs the most common
pathogenic alleles in the general population.
Although m.7445A/G, m.8344A/G, m.8993T/G,
m.13513G/A, and m.14459G/A were not detected,
these mutations are also uncommon in mitochondrial-dis-
ease patients from the same UK population.
3,6 By contrast,
the most common heteroplasmic mutation was
m.3243A/G (33%), reaching frequencies similar to that
described in one mutation-speciﬁc survey.
20 m.3243A/
G is also the most common heteroplasmic mtDNA muta-
tion in adults with mtDNA disease from the same geo-
graphic region (40%).
6 Therefore, a high mutation rate
provides the likely explanation for the prevalence of
m.3243A/G in disease cohorts. By contrast, the carrier
frequencies of the three major mutations that cause Leber
hereditary optic neuropathy (LHON), m.3460G/A,
m.11778G/A, and m.14484T/C, were equal. This differs
from the distribution for independent families with LHON
inthe north ofEngland, where the majority ofcases harbor
the m.11778G/A mutation (60%).
19 All of the asymp-
tomatic m.14484T/C carriers belonged to mtDNA
haplogroup J. This is in keeping with the well-established
preferential association between haplogroup J and
m.14484T/C LHON pedigrees ascertained through clini-
cally affected individuals.
24,25 However, the data shown
here provide the ﬁrst direct evidence that this association
is not due solely to enhanced clinical expression on J,
as previously thought.
10 Subhaplogroup analysis by
mtDNA D-loop sequencing conﬁrmed the independent
recurrence of m.14484T/C in asymptomatic carriers
within the population, providing independent evidence
that haplogroup J predisposes the mitochondrial genome
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258 The American Journal of Human Genetics 83, 254–260, August 8, 2008to mutate at np.14484, possibly through near-neighbor
effects as previously described to occur during mtDNA
evolution.
26
In the heteroplasmic carriers, heteroplasmy levels were
evenly distributed above and below the mean, as expected
from population-genetic theory based on neutral alleles.
27
Of the heteroplasmic offspring with matched maternal
samples, the proportion of mutated mtDNA increased
with transmission in each case. Although this could be ev-
idence of genetic selection during transmission, the per-
centage level of m.3243A/G in blood decreases exponen-
tially during life,
15,21,22 so it is highly likely that some of
these mothers originally had higher levels of m.3243A/
G, making it difﬁcult to draw ﬁrm conclusions. In > 1i n
1000 live births, an mtDNA mutation was present in
cord blood from the child but not detectable in the
mother’s blood, providing an estimation of the de novo
mutation rate. It is conceivable that the maternal levels
of heteroplasmy were below the detection threshold of
the assay, possibly because the level of mutation in blood
decreased during the mother’s life.
15,21,22 However, the
level of sensitivity for ﬂuorescent PCR-RFLP is in the region
of 1.8%,
28 making this unlikely.
Detecting heteroplasmic mtDNA mutations in >1 in 200
individuals of the background population has implications
for studies reporting mtDNA mutations in speciﬁc disease
groups. Our data show that putative disease associations,
such as the reported high frequency of m.3243A/G in di-
abetes mellitus,
23,29–31 could be a chance ﬁnding irrelevant
to pathogenesis. We have identiﬁed a massive reservoir of
pathogenic mtDNA mutations in the general population,
placing greater emphasis on developing techniques to
prevent the transmission of pathogenic alleles that could
segregate to high levels and thus cause mtDNA diseases in
subsequent generations.
Supplemental Data
Supplemental data include three tables and can be found with this
article online at http://www.ajhg.org/.
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